title: Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: use of dasatinib and reduced-conditioning stem-cell transplantation.
authors.forename: S
authors.initials: S
authors.lastname: Corm
authors.forename: A
authors.initials: A
authors.lastname: Renneville
authors.forename: E
authors.initials: E
authors.lastname: Rad-Quesnel
authors.forename: N
authors.initials: N
authors.lastname: Grardel
authors.forename: C
authors.initials: C
authors.lastname: Preudhomme
authors.forename: B
authors.initials: B
authors.lastname: Quesnel
mesh_terms: D000328:Adult; D000368:Aged; D001549:Benzamides; D000069439:Dasatinib; D019008:Drug Resistance, Neoplasm; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics* / Q000502:physiology*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D000068877:Imatinib Mesylate; D007947:Leukemia, Megakaryoblastic, Acute / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology* / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000737:chemistry; D013844:Thiazoles / Q000627:therapeutic use; D019172:Transplantation Conditioning; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D011993:Recombinant Fusion Proteins; D013844:Thiazoles; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; D000069439:Dasatinib